A phase I/IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Aramchol in children with non-alcoholic fatty liver disease

Trial Profile

A phase I/IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Aramchol in children with non-alcoholic fatty liver disease

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Aramchol (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ARTISAN
  • Most Recent Events

    • 03 Oct 2016 New trial record
    • 23 Sep 2016 According to a Galmed Pharmaceuticals media release, this trial is planned to be initiated in the first half of 2017. Galmed signed an investigator-initiated clinical trial agreement with the University of California, San Diego, School of Medicine for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top